Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10459937 | 0.84 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2DRD2DRD3ADORA2B | |
| SCHEMBL9659383 | 0.84 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2DRD2DRD3ADORA2B | |
| SCHEMBL13592654 | 0.84 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2DRD2DRD3ADORA2B | |
| SCHEMBL4406118 | 0.81 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2DRD2DRD3ADORA2B | |
| SCHEMBL1064969 | 0.81 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2DRD2DRD3ADORA2B | |
| SCHEMBL10460009 | 0.81 | LMNA (0.48) | LMNASMN1; SMN2DRD2DRD3ADORA2B | |
| SCHEMBL10338717 | 0.79 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2DRD2DRD3MEN1 | |
| SCHEMBL4407432 | 0.77 | ADORA2B (0.48) | LMNASMN1; SMN2ELANECYP3A4ADORA2B | |
| SCHEMBL7995762 | 0.77 | BRD4 (0.48) | LMNASMN1; SMN2ADORA2BMEN1KMT2A | |
| SCHEMBL4406453 | 0.75 | ADORA2B (0.44) | LMNASMN1; SMN2DRD2DRD3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268641-B1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT LTD (IN) | 2014-09-03 | — | — | EP | disclosed |
| EP-2268641-B1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT LTD (IN) | 2014-09-03 | — | — | EP | disclosed |
| US-8252797-B2 | Heterocyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2012-08-28 | — | — | US | disclosed |
| US-8252797-B2 | Heterocyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2012-08-28 | — | — | US | disclosed |
| US-8252797-B2 | Heterocyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2012-08-28 | — | — | US | disclosed |
| CN-102015712-A | Heterocyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS PVT LTD | 2011-04-13 | — | — | CN | disclosed |
| EP-2268641-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | Advinus Therapeutics Pvt. Ltd. (IN) | 2011-01-05 | — | — | EP | disclosed |
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2009-12-03 | — | — | US | disclosed |
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2009-12-03 | — | — | US | disclosed |
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2009-12-03 | — | — | US | disclosed |
| WO-2009118759-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD., (IN) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118759-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD., (IN) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA1 | LMNA 2164/4885SMN1; SMN2 3103/4885DRD2 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.